Company Filing History:
Years Active: 2021-2024
Title: Innovations in Cancer Treatment by Inventor Eyal Jacob
Introduction
Eyal Jacob, a prominent inventor based in Haifa, Israel, has made significant contributions to cancer treatment through his innovative research. With a total of three patents to his name, his work focuses on novel therapeutic strategies that enhance the efficacy of existing cancer treatments.
Latest Patents
Eyal Jacob's latest patents showcase his groundbreaking approaches to cancer therapy. The first patent, titled "Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy," introduces blocking agents that inhibit IL-1α, IL-1β, or IL-1R activity. This combination aims to improve outcomes for cancer patients undergoing radiotherapy, particularly those whose treatment induces IL-1 factors in their circulation.
His second patent, "Cancer process evaluation," outlines a method for selecting therapeutic agents by analyzing protein data from biological samples. This process involves classifying protein levels into process classes, calculating process scores to assess their relevance to cancer treatment resistance, and selecting targeted therapeutic agents accordingly. Systems for implementing these selections are also provided in the patent.
Career Highlights
Eyal Jacob is associated with Oncohost Ltd., a company that specializes in developing advanced cancer treatment solutions. His innovative work enhances the understanding of cancer biology and contributes to creating more effective treatment plans for patients.
Collaborations
In his endeavors, Eyal collaborates with talented professionals such as Yuval Shaked and Ella Fremder. These collaborations enrich his research and contribute to advancing their shared goals in cancer treatment innovation.
Conclusion
Eyal Jacob's patents and collaborative efforts at Oncohost Ltd. exemplify the potential of innovative thinking in the healthcare sector. His commitment to improving cancer treatment through scientific research significantly benefits patients and underscores his role as a key contributor in the field of oncology.